Date post: | 15-Jun-2015 |
Category: |
Health & Medicine |
Upload: | cell-therapy-catapult |
View: | 191 times |
Download: | 4 times |
Catapult is a Technology Strategy Board programme
Growing a UK Cell Therapy Industry Delivering
Health & Wealth
Matthew Durdy, Chief Business Officer December 2013 ct.catapult.org.uk
The Cell Therapy (and Regenerative Medicine) Opportunity
2
*US Market data • http://www.cancer.org/cancer/cancerbasics/economic-impact-of-cancer • http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf • http://www.cdc.gov/heartdisease/facts.htm • http://www.pdf.org/en/parkinson_statistics • http://www.provengehcp.com/FAQs.aspx • http://www.dermagraft.com/about/efficacy/
Why a Catapult?
• Learning
• Excellence
• Leadership
• Efficiency
• Risk taking
3
Assets -Facilities and Teams
• Facilities • 1200 sq m on 12th floor • Capacity for 80-100 people • Clinical research cluster • Global location
• Business Team • Business development • Health economics • Business models
• Translational Labs and Team • Process development • Analytical development • GMP process proving
• Clinical Trial and Regulatory Team
• Regulatory • Clinical operations
4
Management Team and Board
5
Keith Thompson Chief Executive (Director, Scottish National Blood transfusion Service, Serologicals)
Dr Natalie Mount Chief Clinical Officer (Director Pfizer, Neusentis. Cambridge, UCL)
Dr Stephen Ward Chief Operating Officer (Director, Stabilitech, Onyvax. Southampton, Imperial)
Matthew Durdy Chief Business Officer (Director, Aqix, Biotec, CDC. Oxford, Chicago)
Dr John Brown, CBE, FRSE Chairman BTG plc, Acambis, CAT
Professor Marc Turner Non-executive Director Edinburgh, SNBTS
Tim Edwards Non-executive Director Chairman, Bio Industry Association
Professor Michael Whitaker Non-executive Director NE Stem Cell Institute
Dr Zahid Latif Non-executive Director Technology Strategy Board
Nick Higgins Non-executive Director Consort Medical, Intercytec
Professor Johan Hyllner Chief Scientific Officer (Director, Cellectis, Cellartis, Vitrolife)
Headcount: 65 22/11/2013
Catapult is a Technology Strategy Board programme
Catapult Themes Risk
Management of Perceived Risk
Solution Nature Example
Risk?
EU Regulation
Not Understood
Expert Advice
Economics Not Clear Prepare Data
GMP Not done Expert partner
Therapy Not proven Share
7
Catapult is a Technology Strategy Board programme
Catapult Themes Funding
Need
• Patient • Clinician • Payer • Seller
Group • Identity • Quantity • Diagnostic
Product • Substance • Process • Regulation • Information
Tasks • Innovation • Quality • Data
Commercial Development Plan
9
Start Commercial
Development Plan
?
Govt. Support
Medical Charities
Financial Investment
Corporate Venturing
Funding for cell therapy in the UK
10
Commercial Development Plan
Successful commercialization depends on both regulatory approval and optimal market access
Quality Safety Efficacy Comparative Clinical & Cost-Effectiveness; Budget Impact
REGULATORY APPROVAL MARKET ACCESS
11
Lab - Pilot - Scale
Commercial Scale
12
Catapult GMP Proving Lab
Catapult Multi Functional development Pod
Tech t ransfer
Collaboration
1+1 = 3
Client knowledge + Expert capabilities = Better outcome
Partner Project Input
Funding Ratio
TSB Grant
SME £1m 60% £0.6m Catapult £1m 100% £1.0m Total £2m £1.6m
80%
Up to 80% UK Technology Strategy Board Funding available for collaboration with SME
Sharing the outputs and opportunities
14
Partners
• Cooperation on manufacturing platforms
• Project sourcing and funding
• International collaboration
15
Project Examples
16
Large Cap Company
• New delivery device to reduce injection pain
• Share of expertise • Support for in house projects
• Phase 2 clinical trials • Scale up, Assays, Freezing and distribution
of cells
• Manufacturing partner, Regulatory, Clinical trial design and delivery
• Immunomodulation • Regulatory, Clinical trial design, business
models
• Commercial Development Plan
Activities
Proof of Principle • Scientific, clinical, regulatory, commercial
Non-clinical • Safety, toxicology, GMP proving, assays
Clinical • Safety and efficacy, investible data
Platform • Generic issues and large collaborations
17
Suitability
18
Working models and finance
Nature of project Paid for by: Carried out by:
Ownership of outputs Finance
Core Project Catapult Catapult Catapult £70m/ 5 years
Contracted Development
Client Catapult Client £10m/ Per year
Industry Collaboration
Grant or Catapult and partner
Catapult and partner
Outputs shared
£10m/ Per year
Gateway Criteria
Blood
Bone & Cartilage
Cardiovascular
Dermatology/Wound Healing
Diabetes
Gastroenterology
Immunology
Liver
Metabolic
Neurological
Oncology
Ophthalmology
Respiratory
Other
hESC iPS MSC Immune Cell
Other Somatic
Building the portfolio
Outputs
Life changing therapies Investible propositions Industry changing innovation Skilled leaders UK leadership
Summary: The Cell Therapy Catapult
Strong first year of growth Laboratories and teams up and running, 60+ Large and small collaborations Global interaction Industry success is our success
Matthew Durdy [email protected] http://ct.catapult.org.uk Twitter: @CTCatapult
Catapult is a Technology Strategy Board programme
Industry
Cell Therapy Catapult
Investment
Researchers
NHS